Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Acelot logo — A new paradigm for neurodegeneration.

Acelot

A new paradigm for neurodegeneration.

Founded 2006 United States South San Francisco, United States 17 employees Grant Biotechnology, Health Care +3

General Information

Company Name Acelot
Founded Year 2006
Location United States South San Francisco, United States +1
Employees 17
Industries Biotechnology, Health Care, Health and Wellness +2
Funding Stage Grant
Social

Get notified when Acelot moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Acelot

Acelot is treating functional protein misfolding diseases where the appropriate therapeutic mechanism is a restoration of the normal protein homeostasis. Functional misfolded proteins are found in various diseases such as ALS, FTD, Parkinson’s, diabetes and cancer. Acelot’s platform combines generative AI, molecular dynamics simulations and proprietary assays to discover small molecules that restore the homeostasis of misfolded proteins in various diseases. We have a pipeline of hit-to-lead discovery compounds across multiple indications, along with an IND-ready candidate for ALS. Our platform was invented by UCSB Computer Science Professor Dr. Ambuj Singh. Acelot’s first development candidate, ACE-2223, is a first-in-class orally bioavailable small molecule that will undergo IND-enabling studies in 2024. ACE-2223 disrupts the misfolded forms of TDP43 and restores functional TDP43. It acts upon the misfolded conformations of TDP43 found across various patient populations, including ALS, FTD and Alzheimer’s. ACE-2223 has excellent brain penetrance and ADME properties. Acelot also has a robust discovery pipeline.

No funding data available for Acelot yet.

Get notified when Acelot raises funding

Acelot Alternatives & Competitors

Acelot vs
Avilar Therapeutics
Avilar Therapeutics United States

Pioneering the discovery and development of extracellular protein degraders.

Seed
25 employees
Biotechnology, Pharmaceutical
Acelot vs
Shanghai Junshi Biosciences Co Ltd
Shanghai Junshi Biosciences Co Ltd China

an innovation-driven biopharmaceutical company dedicated to the discovery and development of innovat...

210 employees
Acelot vs
Onena Medicines
Onena Medicines Switzerland

AI-centric preclinical company discovering and developing novel biopharmaceuticals to treat cancer a...

Unknown
9 employees
Biotechnology, Health Care

FAQ About Acelot

A new paradigm for neurodegeneration.
Acelot was founded in 2006.
Acelot is headquartered in South San Francisco, United States.
Acelot operates in the following industries: Biotechnology, Health Care, Health and Wellness, Life Sciences, Pharmaceutical.
Acelot has approximately 17 employees.
Top alternatives and competitors to Acelot include Avilar Therapeutics, Shanghai Junshi Biosciences Co Ltd, Onena Medicines, Biocon. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Acelot and Avilar Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Acelot and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy